PACB vs. ARDX
PACB (Pacific Biosciences of California, Inc.) and ARDX (Ardelyx, Inc.) are both stocks. Both are in the Healthcare sector — PACB in Diagnostics & Research, ARDX in Biotechnology. Over the past 10 years, PACB returned -16.69%/yr vs -2.60%/yr for ARDX. At a 0.26 correlation, their price movements are largely independent.
Performance
PACB vs. ARDX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PACB achieves a -29.95% return, which is significantly lower than ARDX's 6.00% return. Over the past 10 years, PACB has underperformed ARDX with an annualized return of -16.69%, while ARDX has yielded a comparatively higher -2.60% annualized return.
PACB
- 1D
- -0.76%
- 1M
- 7.38%
- YTD
- -29.95%
- 6M
- -28.02%
- 1Y
- 10.08%
- 3Y*
- -52.85%
- 5Y*
- -47.38%
- 10Y*
- -16.69%
ARDX
- 1D
- -2.98%
- 1M
- 1.15%
- YTD
- 6.00%
- 6M
- 6.55%
- 1Y
- 70.25%
- 3Y*
- 19.74%
- 5Y*
- -4.70%
- 10Y*
- -2.60%
PACB vs. ARDX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PACB Pacific Biosciences of California, Inc. | -29.95% | 2.19% | -81.35% | 19.93% | -60.02% | -21.13% | 404.67% | -30.54% | 180.30% | -30.53% |
ARDX Ardelyx, Inc. | 6.00% | 14.99% | -18.23% | 117.54% | 159.09% | -83.00% | -13.79% | 319.27% | -72.88% | -53.52% |
Correlation
The correlation between PACB and ARDX is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Jun 19, 2014 | 0.26 |
Fundamentals
PACB:
$400.62M
ARDX:
$1.52B
PACB:
-$0.43
ARDX:
-$0.24
PACB:
2.47
ARDX:
3.51
PACB:
3.82
ARDX:
10.22
PACB:
$160.03M
ARDX:
$427.68M
PACB:
$59.34M
ARDX:
$395.63M
PACB:
-$146.34M
ARDX:
-$28.55M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PACB vs. ARDX — Risk / Return Rank
PACB
ARDX
PACB vs. ARDX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and Ardelyx, Inc. (ARDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PACB | ARDX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.03 | ||
| Sortino ratioReturn per unit of downside risk | -1.29 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.26 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 0.17 | 2.11 | -1.93 |
| Martin ratioReturn relative to average drawdown | 0.32 | 4.07 | -3.75 |
Loading charts...
Drawdowns
PACB vs. ARDX - Drawdown Comparison
The maximum PACB drawdown since its inception was -98.22%, roughly equal to the maximum ARDX drawdown of -98.45%. Use the drawdown chart below to compare losses from any high point for PACB and ARDX.
Loading charts...
Drawdown Indicators
| PACB | ARDX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.22% | -98.45% | +0.23% |
Max Drawdown (1Y)Largest decline over 1 year | -58.05% | -33.54% | -24.51% |
Max Drawdown (3Y)Largest decline over 3 years | -93.47% | -66.32% | -27.15% |
Max Drawdown (5Y)Largest decline over 5 years | -97.47% | -93.76% | -3.71% |
Max Drawdown (10Y)Largest decline over 10 years | -98.22% | -96.82% | -1.40% |
Current DrawdownCurrent decline from peak | -97.44% | -81.21% | -16.23% |
Average DrawdownAverage peak-to-trough decline | -70.57% | -77.37% | +6.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.59% | 17.31% | +14.28% |
Volatility
PACB vs. ARDX - Volatility Comparison
Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 22.24% compared to Ardelyx, Inc. (ARDX) at 12.95%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than ARDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PACB | ARDX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.24% | 12.95% | +9.29% |
Volatility (6M)Calculated over the trailing 6-month period | 56.24% | 46.39% | +9.85% |
Volatility (1Y)Calculated over the trailing 1-year period | 87.49% | 61.42% | +26.07% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.44% | 89.49% | +4.95% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 84.70% | 83.99% | +0.71% |
Dividends
PACB vs. ARDX - Dividend Comparison
Neither PACB nor ARDX has paid dividends to shareholders.
Financials
PACB vs. ARDX - Financials Comparison
This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and Ardelyx, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
PACB and ARDX have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PACB has higher volatility (22.24%) compared to ARDX (12.95%). In terms of maximum drawdown, PACB dropped -98.22% vs ARDX's -98.45%.
ARDX currently has the higher Sharpe Ratio (1.15 vs 0.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PACB and ARDX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer